 AUSTIN, Texas, June 16, 2021 PRNewswire -- Natera,Inc. NASDAQ: NTRA, a pioneer and global leader in cell-free DNA testing, today announced the publication of a new study in Nature, validating the ability of its personalized and tumor-informed circulating tumor DNA ctDNA assay, Signatera, to predict outcomes with immunotherapy in a randomized clinical trial. The study, which can be found here , is Signateras 12th peer-reviewed publication and is the first publication that shows the predictive capabilities of a molecular residual disease MRD test in a large, randomized, multi-center study. 